TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2829259

Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg i.v.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 6
Study: 30982443

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (300,000 IU, single muscular injection)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (1 ml, Placebo group)
Number of subjects: 90
Study: 30509754

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27795561

Group type: EXPERIMENTAL
Intervention: Azacitidine and vorinostat
Number of subjects: 30

Group type: COMPARATOR
Intervention: Azacitidine (AZA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Azacitidine and vorinostat (AZA+V)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 30
Study: 26116584

Group type: EXPERIMENTAL
Intervention: TEL group (n = 338)
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: SMS group (n = 335)
Number of subjects: 1003

Group type: COMPARATOR
Intervention: CONTROL group (n = 330)
Number of subjects: 1003
Study: 23375496

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 mg/kg preoperatively
Number of subjects: 40
Study: 21436038

Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone (slow effects)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone (rapid effects)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20184129

Group type: EXPERIMENTAL
Intervention: Combined spinal and general anesthesia block (CSGAB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combined epidural and general anesthesia block (CEGAB)
Number of subjects: 40
Study: 17010635

Group type: EXPERIMENTAL
Intervention: Normal saline solution at 20 degrees C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical papaverine at 20 degrees C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normal saline solution at 37 degrees C
Number of subjects: 60
Study: 15543714

Group type: EXPERIMENTAL
Intervention: Topical tazarotene 0.1% gel or cream once daily for 12 weeks
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Topical tazarotene cream formulation
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Topical tazarotene gel formulation
Number of subjects: 468
Study: 11758661

Group type: EXPERIMENTAL
Intervention: Cognitive treatment package
Number of subjects: 66

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 66
Study: 9156363

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg once daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Felodipine extended‐release 5-10 mg once daily
Number of subjects: 52
Study: 7951339

Group type: EXPERIMENTAL
Intervention: Nerve-sparing retroperitoneal lymph-node dissection (RPLND)
Number of subjects: 0
Study: 3582135

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg b.d. for 5 days
Number of subjects: 385

Group type: COMPARATOR
Intervention: Augmentin 375 mg t.d.s. for 5 days
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 385

Group type: COMPARATOR
Intervention: Augmentin
Number of subjects: 385
Study: 31087564

Group type: COMPARATOR
Intervention: Eribulin mesylate (EM) in third line
Number of subjects: 16703

Group type: COMPARATOR
Intervention: Eribulin mesylate (EM) in fourth line
Number of subjects: 16703

Group type: COMPARATOR
Intervention: Eribulin mesylate (EM) in second line
Number of subjects: 16703

Group type: COMPARATOR
Intervention: Eribulin mesylate (EM) in second line among HER2- patients
Number of subjects: 16703
Study: 28289237

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (clopidogrel-aspirin)
Number of subjects: 2933

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2933
Study: 26411504

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS) containing 90 µg I with 0 or 10 mg Zn, 20 g/day from 9 to 18 months of age.
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (non-intervention cohort) received no SQ-LNS.
Number of subjects: 179
Study: 24261022

Group type: EXPERIMENTAL
Intervention: peg-interferon (peg-IFN) plus ribavirin (RBV)
Number of subjects: 154
Study: 21410297

Group type: EXPERIMENTAL
Intervention: Orally dosed non-(14)C-labeled lesogaberan (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenously infused non-(14)C-labeled lesogaberan (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orally administered (14)C-labeled lesogaberan (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenously administered (14)C-labeled lesogaberan (20 mg)
Number of subjects: 10
Study: 18285436

Group type: EXPERIMENTAL
Intervention: Estimation method using surrogate endpoint in new trial
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypothesis testing method using z-statistic for surrogate endpoint
Number of subjects: 20
Study: 16448895

Group type: EXPERIMENTAL
Intervention: losartan 50 to 100 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: candesartan 8 to 16 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: both losartan and candesartan
Number of subjects: 59
Study: 12562705

Group type: EXPERIMENTAL
Intervention: Tablets 250/125 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Tablets 500/125 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Tablets 875/125 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Oral suspension 250/62.5 mg per 5 mL
Number of subjects: 144
Study: 11524325

Group type: EXPERIMENTAL
Intervention: Epidural morphine injection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no epidural morphine)
Number of subjects: 21
Study: 9674185

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bromocriptine (BEC)
Number of subjects: 39
Study: 8513309

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg o.d. (doubled after 1 month if seated diastolic BP was > or = 95 mmHg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Potassium-Canrenoate (K-Can) 50 mg o.d. (doubled after 1 month if seated diastolic BP was > or = 95 mmHg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both drugs (HCTZ and K-Can)
Number of subjects: 26
Study: 2872804

Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 40 mg once daily)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 31407323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different methodological procedures in PCRPS
Number of subjects: 0
Study: 28926353

Group type: COMPARATOR
Intervention: Lacosamide 200 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lacosamide 800 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Alprazolam 3 mg
Number of subjects: 38
Study: 25376971

Group type: EXPERIMENTAL
Intervention: General anesthesia plus Pecs block (Pecs group, n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia alone (control group, n = 60)
Number of subjects: 120
Study: 25474391

Group type: EXPERIMENTAL
Intervention: Function-focused care (FFC) for assisted living intervention (FFC-AL)
Number of subjects: 171
Study: 21072736

Group type: EXPERIMENTAL
Intervention: Balance and strength training for 8 weeks at the worksite
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Detraining after 8 weeks of training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 19117563

Group type: EXPERIMENTAL
Intervention: Two layers of cotton underpadding
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Four layers of cotton underpadding
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both cast designs
Number of subjects: 45
Study: 17120972

Group type: EXPERIMENTAL
Intervention: Single dose Vi polysaccharide vaccine (Typherix)
Number of subjects: 32267

Group type: COMPARATOR
Intervention: Active control hepatitis A vaccine (Havrix)
Number of subjects: 32267
Study: 15257908

Group type: EXPERIMENTAL
Intervention: Ultrafiltration with AN69 membrane (adsorption group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ultrafiltration with polysulfone (PS) membrane (control group)
Number of subjects: 30
Study: 11275505

Group type: EXPERIMENTAL
Intervention: General practice methadone maintenance treatment
Number of subjects: 125

Group type: COMPARATOR
Intervention: Drug clinic methadone maintenance treatment
Number of subjects: 125
Study: 9284777

Group type: EXPERIMENTAL
Intervention: hPTH [1-34], 400 U/25 micrograms daily subcutaneously
Number of subjects: 34

Group type: COMPARATOR
Intervention: Hormone-replacement therapy only (Control)
Number of subjects: 34
Study: 8392359

Group type: EXPERIMENTAL
Intervention: Extradural bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic opioids
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both techniques (Extradural bupivacaine and Systemic opioids)
Number of subjects: 40
Study: 2437455

Group type: EXPERIMENTAL
Intervention: Etoposide with cisplatin and bleomycin
Number of subjects: 261

Group type: COMPARATOR
Intervention: Vinblastine with cisplatin and bleomycin
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Etoposide with cisplatin and bleomycin (high tumor volume)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Vinblastine with cisplatin and bleomycin (high tumor volume)
Number of subjects: 261
Study: 29131664

Group type: EXPERIMENTAL
Intervention: Corticotomy performed on the test side
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control side (noncorticotomized)
Number of subjects: 8
Study: 27511844

Group type: EXPERIMENTAL
Intervention: Cetux‐FHX (cetuximab, 5‐fluorouracil, hydroxyurea, and 1.5 Gy twice‐daily radiation therapy every other week to 75 Gy)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cetux‐PX (cetuximab, cisplatin, and accelerated radiation therapy with delayed concomitant boost to 72 Gy in 42 fractions)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cetux‐FHX
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cetux‐PX
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: HPV-positive patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: HPV-negative patients
Number of subjects: 110
Study: 23736964

Group type: EXPERIMENTAL
Intervention: Culturally-targeted patient navigation (PN)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Standard patient navigation (PN)
Number of subjects: 392
Study: 23067912

Group type: EXPERIMENTAL
Intervention: System delay 0 to 120 minutes
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: System delay 121 to 180 minutes
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: System delay >180 minutes
Number of subjects: 219
Study: 20735366

Group type: EXPERIMENTAL
Intervention: Mood management intervention (integration of control intervention with a mood management component including a self-help manual, two additional proactive telephone sessions, and homework assignments)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control intervention (eight sessions of proactive telephone counselling)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Mood management intervention
Number of subjects: 485
Study: 17226852

Group type: EXPERIMENTAL
Intervention: Warfarin therapy in children with heterozygous CYP2C9 polymorphisms
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Warfarin therapy in children on concomitant corticosteroids
Number of subjects: 29
Study: 16114787

Group type: COMPARATOR
Intervention: Epoetin alfa 20,000 U every two weeks (Q2W)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Epoetin alfa 30,000 U every three weeks (Q3W)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 U every four weeks (Q4W)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 10,000 U once weekly (QW)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Quality of life assessment across all dosing groups
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Safety evaluation of epoetin alfa
Number of subjects: 519
Study: 12134227

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 33
Study: 10405232

Group type: EXPERIMENTAL
Intervention: Triple therapy using omeprazole (30 mg twice a day) plus clarithromycin (500 mg twice a day) and amoxicillin (1 g twice a day)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Triple therapy using lansoprazole (30 mg twice a day) plus clarithromycin (500 mg twice a day) and amoxicillin (1 g twice a day)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Triple therapy using omeprazole or lansoprazole plus clarithromycin and amoxicillin
Number of subjects: 143
Study: 7562290

Group type: EXPERIMENTAL
Intervention: Lactose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactose-glucose polymer combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose polymers alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactose-glucose polymer combination and glucose polymers alone
Number of subjects: 0
Study: 1536959

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (8 micrograms glycoprotein (5.5 micrograms protein)/kg/d, continuous IV infusion for 14 days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 6509876

Group type: EXPERIMENTAL
Intervention: Prompt phenytoin sodium capsules (divided doses)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Prompt phenytoin sodium capsules (single doses)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Extended phenytoin sodium capsules
Number of subjects: 5

Group type: COMPARATOR
Intervention: Phenytoin sodium injection
Number of subjects: 5
Study: 31891298

Group type: EXPERIMENTAL
Intervention: Modified 2-stage inferior alveolar nerve block (IANB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional 2-stage inferior alveolar nerve block (IANB)
Number of subjects: 64
Study: 30311896

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 grams IV 24 hours preoperatively, 500 mg every 12 hours IV for 48 hours in ICU, and 500 mg every 12 hours PO for 48 hours in ward)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (no vitamin C)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 314
Study: 24361097

Group type: EXPERIMENTAL
Intervention: Schirmer test with anesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Schirmer test without anesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inferior gaze position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Palpebral aperture, age, and OSDI questionnaire
Number of subjects: 20
Study: 22337646

Group type: EXPERIMENTAL
Intervention: Spouse-assisted coping skills training protocol for patients undergoing a multidisciplinary pain management programme (SA-MPMP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional patient-oriented multidisciplinary pain management programme (P-MPMP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 36
Study: 19575366

Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg peginterferon alfa-2b weekly plus 800-1,400 mg ribavirin daily for 48 weeks (group A)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Individually tailored treatment duration (18-48 weeks; group B)
Number of subjects: 433
Study: 17855692

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-fruit and -vegetable diet
Number of subjects: 801

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 801
Study: 15073109

Group type: EXPERIMENTAL
Intervention: Tamoxifen 1 mg daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tamoxifen (all doses)
Number of subjects: 120
Study: 11199932

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg starting dose for 12 weeks or 25 mg starting dose for 10 weeks)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705

Group type: COMPARATOR
Intervention: Sertraline and Placebo
Number of subjects: 705
Study: 9753259

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every morning
Number of subjects: 472

Group type: COMPARATOR
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 472
Study: 8172800

Group type: EXPERIMENTAL
Intervention: ELF regimen (A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified ELF regimen (B)
Number of subjects: 40
Study: 3065016

Group type: EXPERIMENTAL
Intervention: Combined administration of human zinc insulin (Monotard HM) with soluble human insulin (Actrapid HM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Separate administration of human zinc insulin (Monotard HM) with soluble human insulin (Actrapid HM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined administration of protamine insulin (Protaphan HM) with soluble human insulin (Actrapid HM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Separate administration of protamine insulin (Protaphan HM) with soluble human insulin (Actrapid HM)
Number of subjects: 8
Study: 30148731

Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits and HIV testing information (study arm 3)
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Standard-of-care and a standard information card (study arm 1)
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Improved card stating the importance of male HIV testing (study arm 2)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits
Number of subjects: 1410
Study: 27002770

Group type: EXPERIMENTAL
Intervention: Exposure to interpersonal violence in the home
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Exposure to community violence
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Harsh physical discipline
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Exposure to home and community violence
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Ongoing participation in the community-based programme
Number of subjects: 989
Study: 24726205

Group type: EXPERIMENTAL
Intervention: 4Ts score of 3 or lower (low pretest probability of HIT)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: 4Ts score of 4-5 (moderate pretest probability of HIT)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: 4Ts score of ≥6 (high pretest probability of HIT)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Agreement between research coordinators and central adjudication
Number of subjects: 794
Study: 22897985

Group type: EXPERIMENTAL
Intervention: Local topical anesthesia (LT) with 5% lidocaine and 5% prilocaine cream
Number of subjects: 41

Group type: COMPARATOR
Intervention: Dorsal penile nerve block (DPNB) with 0.5% bupivacaine (1 mg/kg)
Number of subjects: 41
Study: 19484485

Group type: COMPARATOR
Intervention: Conventional low-stretch compressive bandaging
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Alginate semi-rigid bandage
Number of subjects: 61
Study: 17961161

Group type: EXPERIMENTAL
Intervention: ERCC1-negative tumors
Number of subjects: 159

Group type: COMPARATOR
Intervention: ERCC1-positive tumors
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: T/T genotype
Number of subjects: 159
Study: 16428249

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for two weeks
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study: 14636765

Group type: EXPERIMENTAL
Intervention: 0.25% povidone iodine subeschar clysis (PVP‐SEC) in addition to surface application of povidone iodine + Neosporin
Number of subjects: 613

Group type: COMPARATOR
Intervention: Crust application only (control group)
Number of subjects: 613
Study: 10688395

Group type: EXPERIMENTAL
Intervention: Troglitazone + glyburide
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Glyburide alone
Number of subjects: 1000
Study: 9678123

Group type: EXPERIMENTAL
Intervention: Low-dose monophasic combined oral contraceptive (100 micrograms levonorgestrel/20 micrograms ethinylestradiol)
Number of subjects: 15
Study: 1337160

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo) at target Hb 9 g/dl
Number of subjects: 12
Study: 3986113

Group type: EXPERIMENTAL
Intervention: Nebulized lignocaine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nebulized lignocaine without diazepam
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bolus lignocaine
Number of subjects: 52
Study: 30024484

Group type: EXPERIMENTAL
Intervention: Experimental group (provided FMS grading criteria)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not provided FMS grading criteria)
Number of subjects: 32
Study: 31675102

Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675 mg at baseline, 225 mg at weeks 4 and 8)
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: All fremanezumab groups (quarterly and monthly combined)
Number of subjects: 1130
Study: 30404123

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided betamethazone injections
Number of subjects: 44

Group type: COMPARATOR
Intervention: Blind injections (palpation-guided)
Number of subjects: 44
Study: 27385305

Group type: EXPERIMENTAL
Intervention: Biological therapy (adalimumab, etanercept, infliximab, ustekinumab)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no systemic therapy)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Biological therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 25207986

Group type: EXPERIMENTAL
Intervention: TAU + CBT (16 sessions individual CBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 60
Study: 22911048

Group type: EXPERIMENTAL
Intervention: Interactive computerized patient education, skin self-examination tutorials, and telecommunication reminders for 12 weeks.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Brochure on melanoma detection (control group).
Number of subjects: 132